jump to navigation

Cancer treatment developer GammaCan raised $6.5 million March 6, 2007

Posted by israelhealthcare in Drug Discovery.
Tags: , ,
trackback

GammaCan, a developer of novel immunotherapies to treat cancer, raised $6.5 million in a private placement with a group of investors lead by T.R. Winston & Company.

“These funds will enable us to continue the development of VitiGam for the treatment of Stage III and Stage IV melanoma,” said Patrick Schnegelsberg, CEO.

GammaCan develops innovative immunotherapy and related approaches to treat cancer. GammaCan is planning to submit its Investigational New Drug Application (IND) for VitiGam to the FDA in the near future. The Company is expecting to commence human clinical trials shortly thereafter.

VitiGam is a first-in-class IgG-based anti-cancer immunotherapy being developed for the treatment of Stage III and Stage IV melanoma. VitiGam is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition affecting up to 2% of the general population.

Sponsored Links – Garlic Grinder | Sequential Compression Device | Derma Skin Care Ointments

Advertisements

Comments»

No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: